Thomas Bartl

16PUBLICATIONS
25CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunologyObstetrics and gynaecologyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Nov 26, 2025
Novel Treatment Concepts for Cervical Cancer-Moving Towards Personalized Therapy.

Melina Danisch, Magdalena Postl, Thomas Bartl

|Sep 27, 2025
Therapeutic Effects of Lurbinectedin in PARP Inhibitor-Resistant High-Grade Serous Ovarian Cancer Using Patient-Derived Cell Lines and Organoid Models.

Akshi Srivastava, Christine Unterweger, Sarah Guttmann

|May 12, 2025
Oncologic outcome of metachronous oligometastatic recurrence in advanced cervical cancer patients after primary radio-chemotherapy.

Thomas Bartl, Tim Dorittke, Cristina Ciocsirescu

|Oct 16, 2024
The Predictive Value of the Fibrinogen-Albumin-Ratio Index on Surgical Outcomes in Patients with Advanced High-Grade Serous Ovarian Cancer.

Magdalena Postl, Melina Danisch, Fridolin Schrott

|Oct 16, 2024
Novel Targeted Agents in Advanced and Recurrent Low-Grade Serous Ovarian Cancer: A Silver Lining in the Therapy of a Chemoresistant Disease?

Arina Onoprienko, Thomas Bartl, Christoph Grimm

|Oct 07, 2024
Metastasized inflammatory myofibroblastic tumor of uterine origin.

Thomas Bartl, Michael Deavers, Ryan Blair Kieser

Pageof 3

Frequent Collaborators

10 joint publications

Grimm Christoph

6 joint publications

Stephan Polterauer

3 joint publications

Melina Danisch

2 joint publications

Pedro T Ramirez